Atara Biotherapeutics Inc (ATRA) CEO Isaac E. Ciechanover Sells 28,700 Shares

Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 28,700 shares of the business’s stock in a transaction that occurred on Friday, January 12th. The shares were sold at an average price of $21.39, for a total transaction of $613,893.00. Following the transaction, the chief executive officer now owns 743,675 shares of the company’s stock, valued at $15,907,208.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Atara Biotherapeutics Inc (ATRA) traded up $6.10 during midday trading on Friday, hitting $28.25. 3,693,136 shares of the company’s stock were exchanged, compared to its average volume of 860,738. The company has a market capitalization of $832.75, a PE ratio of -8.14 and a beta of 1.27. Atara Biotherapeutics Inc has a 12-month low of $11.80 and a 12-month high of $30.40.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.05). research analysts forecast that Atara Biotherapeutics Inc will post -4 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC bought a new stake in shares of Atara Biotherapeutics during the third quarter worth $142,000. Voya Investment Management LLC grew its stake in shares of Atara Biotherapeutics by 16.2% in the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 1,651 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Atara Biotherapeutics in the third quarter worth $170,000. State of Wisconsin Investment Board bought a new stake in shares of Atara Biotherapeutics in the second quarter worth $252,000. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Atara Biotherapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after purchasing an additional 1,369 shares during the last quarter. 85.61% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts have weighed in on ATRA shares. BidaskClub raised shares of Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research note on Thursday. Citigroup raised shares of Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 target price on the stock in a research note on Wednesday, January 3rd. ValuEngine raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. Canaccord Genuity reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research note on Friday, December 29th. Finally, Goldman Sachs Group reaffirmed a “neutral” rating and set a $20.00 target price on shares of Atara Biotherapeutics in a research note on Friday, October 6th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $26.00.

ILLEGAL ACTIVITY WARNING: “Atara Biotherapeutics Inc (ATRA) CEO Isaac E. Ciechanover Sells 28,700 Shares” was first reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.thestockobserver.com/2018/01/13/atara-biotherapeutics-inc-atra-ceo-isaac-e-ciechanover-sells-28700-shares.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply